What are the recommended lifestyle modifications and pharmacologic treatment options for managing essential hypertension?

Essential Hypertension Management

Diagnostic Confirmation

Confirm the diagnosis with out-of-office measurements before initiating treatment. 1, 2

• Office blood pressure ≥140/90 mmHg on repeated measurements defines hypertension, but must be verified with home BP monitoring (≥135/85 mmHg) or 24-hour ambulatory monitoring (≥130/80 mmHg) to exclude white-coat hypertension 1, 2
• Approximately 10% of cases have identifiable secondary causes (primary aldosteronism, renal artery stenosis, obstructive sleep apnea, pheochromocytoma) that should be screened for when BP is severely elevated (≥180/110 mmHg) or resistant to triple therapy 1, 3

---

Lifestyle Modifications (Foundation for All Patients)

Initiate lifestyle modifications simultaneously with pharmacological therapy—not sequentially—as they provide additive BP reductions of 10–20 mmHg. 2, 3

• Sodium restriction to <2 g/day yields 5–10 mmHg systolic reduction and enhances efficacy of all antihypertensive classes, especially diuretics and RAS blockers 3, 2, 4
• DASH dietary pattern (high in fruits, vegetables, whole grains, low-fat dairy; low in saturated fat) reduces BP by approximately 11.4/5.5 mmHg 3, 4
• Weight reduction to BMI 20–25 kg/m²: losing ~10 kg decreases BP by 6.0/4.6 mmHg 3, 2
• Regular aerobic exercise (≥30 minutes most days, ~150 minutes/week moderate intensity) lowers BP by 4/3 mmHg 3, 2, 4
• Alcohol limitation to ≤2 drinks/day for men, ≤1 drink/day for women (or ≤100 g/week total) 3, 2
• Smoking cessation is mandatory, as continued smoking negates the cardiovascular benefit of BP control 3

---

Blood Pressure Targets

Target <130/80 mmHg for most adults; minimum acceptable goal is <140/90 mmHg. 3, 2, 4

• For higher-risk patients (diabetes, chronic kidney disease, established cardiovascular disease), the target is <130/80 mmHg 2, 4
• For elderly patients (≥65 years), target systolic <130 mmHg if well tolerated; individualize based on frailty, but do not withhold appropriate treatment solely based on age 2, 4
• Aim to achieve target BP within 3 months of treatment initiation or modification 1, 2

---

Pharmacological Treatment Algorithm

Stage 1 Hypertension (140–159/90–99 mmHg)

Initiate pharmacological treatment immediately if high cardiovascular risk is present; otherwise, attempt lifestyle modification for 3–6 months first. 1, 3

• First-line monotherapy options: 3, 4, 5

  • ACE inhibitor (e.g., lisinopril 10 mg daily) or ARB (e.g., losartan 50 mg daily)
  • Thiazide-type diuretic (chlorthalidone 12.5–25 mg daily preferred over hydrochlorothiazide due to superior 24-hour BP control and cardiovascular outcomes) 3, 4
  • Calcium channel blocker (amlodipine 5–10 mg daily) 3, 4, 5

• For non-Black patients: Start with ACE inhibitor or ARB 1, 5

• For Black patients: Start with calcium channel blocker or thiazide diuretic (lower renin activity makes these more effective) 1, 5

Stage 2 Hypertension (≥160/100 mmHg)

Start immediately with two-drug combination therapy—preferably in a single-pill combination—to achieve rapid BP control. 3, 2, 4

• Preferred first-line combinations: 3, 2, 4

  • RAS blocker (ACE inhibitor or ARB) + calcium channel blocker
  • RAS blocker (ACE inhibitor or ARB) + thiazide/thiazide-like diuretic
  • Calcium channel blocker + thiazide/thiazide-like diuretic

• Single-pill combinations significantly improve medication adherence and persistence 3, 2

• Dual therapy provides complementary mechanisms (vasodilation + RAS blockade or volume reduction) and reaches BP goals faster than monotherapy dose escalation 3, 4

---

Treatment Escalation for Uncontrolled Hypertension

If BP Remains ≥140/90 mmHg on Monotherapy

Add a second agent from a different class rather than increasing the dose of the first drug. 3, 2, 4

• Adding a second agent yields ~10–20 mmHg systolic reduction, substantially more than dose escalation within the same class 3, 4
• Verify medication adherence first—non-adherence is the most common cause of apparent treatment resistance 3, 2

If BP Remains ≥140/90 mmHg on Dual Therapy (Triple Therapy)

Add a third agent to create the guideline-recommended triple regimen: RAS blocker + calcium channel blocker + thiazide diuretic. 3, 2, 6

• This combination targets three complementary mechanisms: RAS blockade, vasodilation, and volume reduction 3, 2
• Triple therapy achieves BP control in >80% of patients 3, 2
• Allow 2–4 weeks for the full effect of dose adjustments before further changes 2

Resistant Hypertension (BP ≥140/90 mmHg Despite Optimized Triple Therapy)

Add spironolactone 25–50 mg daily as the preferred fourth-line agent. 3, 2, 4

• Spironolactone provides additional reductions of approximately 20–25 mmHg systolic and 10–12 mmHg diastolic when added to triple therapy 3, 2

• It addresses occult volume expansion and aldosterone excess, common mechanisms underlying treatment resistance 3, 2

• Monitor serum potassium and creatinine 2–4 weeks after initiation due to hyperkalemia risk, especially when combined with ACE inhibitor or ARB 3, 2

• Before adding a fourth agent: 3, 2

  • Confirm medication adherence (pill counts, pharmacy refill data, direct questioning)
  • Verify true hypertension with home BP monitoring (≥135/85 mmHg) or 24-hour ambulatory monitoring (≥130/80 mmHg)
  • Screen for secondary hypertension if BP remains severely elevated
  • Review for interfering substances (NSAIDs, decongestants, oral contraceptives, systemic corticosteroids, stimulants, herbal supplements)

• Alternative fourth-line agents if spironolactone is contraindicated: 3

  • Eplerenone 50–200 mg daily
  • Amiloride
  • Doxazosin
  • Vasodilating beta-blockers (carvedilol, nebivolol, labetalol) only if compelling indication exists

---

Monitoring and Follow-Up

See patients every 1–3 months until BP is controlled, then extend to every 3–6 months. 3, 1, 2

• Re-measure office BP 2–4 weeks after any medication change 3, 2, 4
• Check serum potassium and creatinine 2–4 weeks after initiating a diuretic, ACE inhibitor, or ARB to detect electrolyte disturbances or renal function changes 3, 2
• Home BP monitoring is recommended for ongoing assessment of BP control 3, 1
• Repeat ambulatory BP monitoring may be used to assess treatment effectiveness, especially in patients with chronic kidney disease 3

---

Critical Pitfalls to Avoid

• Do not add a beta-blocker as first-, second-, or third-line therapy unless there are compelling indications (angina, post-MI, heart failure with reduced ejection fraction, atrial fibrillation requiring rate control)—beta-blockers are less effective than calcium channel blockers or diuretics for stroke prevention in uncomplicated hypertension 3, 2

• Do not combine an ACE inhibitor with an ARB (dual RAS blockade)—this increases the risk of hyperkalemia, acute kidney injury, and hypotension without added cardiovascular benefit 3, 2

• Do not use non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in patients with left ventricular dysfunction or heart failure due to negative inotropic effects 3

• Do not delay treatment intensification when BP remains ≥140/90 mmHg—prompt action within 2–4 weeks is required to reduce cardiovascular risk 3, 2

• Do not assume treatment failure without first confirming adherence, excluding white-coat hypertension, and ruling out secondary causes or interfering substances 3, 2

• Do not rely on monotherapy dose escalation as the primary strategy for uncontrolled hypertension—combination therapy with agents from different classes is more effective 3, 2, 4